Dados do Trabalho

Título

MUCOPOLYSACCHARIDOSIS III AT THE REFERENCE CENTER FOR RARE DISEASES OF CEARA

Introdução

Mucopolysaccharidosis type III (MPS III) is the type of mucopolysaccharidosis that has fewer systemic signs and symptoms, however, it has the most severe neurological impairment.There are four types of MPS III, determined by the mutation in the gene responsible for the enzyme that becomes deficient in degrading intracellular glycosaminoglycan, which is responsible for the clinical picture

Objetivo

describe the cases of MPS III at a Reference Center for Rare Diseases in Ceará.

Métodos

Quantitative, cross-sectional, retrospective, observational study of MPS III cases from 2000 to 2022 at the Reference Center for Rare Diseases of Ceará. The variables were: type of MPS, sex, age at study, age of onset, age at diagnosis, neurological developmental milestones, neurological signs/symptoms, neuroimaging data, and death (yes/no).

Resultados

We evaluated 12 cases, 6 MPS IIIB, 4 MPS IIIA, and 2 MPS IIIC. Five were female. Three had consanguinity, four had a familial recurrence. The first symptoms occurred between 1 month and 3 years of age and the speech-language disorders were more frequent. The etiological diagnosis was performed between 2-18 years. In all cases, there was a delay in neurodevelopmental milestones. In the clinical picture, the presence of seizures, behavior disorder, intellectual disability, hyperactivity, autism, hydrocephalus, and dysphagia are highlighted. There were three cases of abandonment of follow-up and four deaths, three due to respiratory failure and one due to sepsis in the age group of 13 to 19 years.

Conclusões

Severe neurological impairment is evident in all cases of MPS III. Strategies must be implemented to avoid delay in diagnosis, such as happened in the cases presented, including to enable future treatment with gene therapy, possible only for asymptomatic cases or with initial symptoms.

Palavras chave

Mucopolysaccharidosis III; Metabolism, Inborn Errors; Neurologic Manifestations

Declaração de conflito de interesses de TODOS os autores

declaro que nenhum dos autores do trabalho Mucopolysaccharidosis III at the Reference Center for Rare Diseases of Ceará tem conflito de interesse.
fortaleza 22/08/2022